JP2010509369A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509369A5
JP2010509369A5 JP2009536520A JP2009536520A JP2010509369A5 JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5 JP 2009536520 A JP2009536520 A JP 2009536520A JP 2009536520 A JP2009536520 A JP 2009536520A JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5
Authority
JP
Japan
Prior art keywords
composition
vegf
antibody
use according
average thickness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009536520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/084320 external-priority patent/WO2008063932A2/en
Publication of JP2010509369A publication Critical patent/JP2010509369A/ja
Publication of JP2010509369A5 publication Critical patent/JP2010509369A5/ja
Pending legal-status Critical Current

Links

JP2009536520A 2006-11-10 2007-11-09 加齢黄斑変性症を処置するための方法 Pending JP2010509369A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86538006P 2006-11-10 2006-11-10
PCT/US2007/084320 WO2008063932A2 (en) 2006-11-10 2007-11-09 Method for treating age-related macular degeneration

Publications (2)

Publication Number Publication Date
JP2010509369A JP2010509369A (ja) 2010-03-25
JP2010509369A5 true JP2010509369A5 (2) 2010-12-02

Family

ID=39323041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536520A Pending JP2010509369A (ja) 2006-11-10 2007-11-09 加齢黄斑変性症を処置するための方法

Country Status (6)

Country Link
US (2) US20100111963A1 (2)
EP (1) EP2089059A2 (2)
JP (1) JP2010509369A (2)
AU (1) AU2007323925A1 (2)
CA (1) CA2666709A1 (2)
WO (1) WO2008063932A2 (2)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) * 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
EP2321651B1 (en) 2008-07-23 2017-08-23 F. Hoffmann-La Roche AG Identification of subjects being susceptible to anti-angiogenesis therapy
ES2468827T3 (es) * 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
BR112013009701A2 (pt) * 2010-10-27 2016-07-19 Novartis Ag regimes de dosagem para o tratamento de doença vascular ocular
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
EP2671589A4 (en) * 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY
CA2879597C (en) * 2012-08-21 2021-01-12 Opko Pharmaceuticals, Llc Ophthalmic liposome formulations for treating posterior segment disease
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
WO2015052104A1 (en) * 2013-10-08 2015-04-16 F. Hoffmann-La Roche Ag Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro- 5-trifluoromethyl-benzamide for the treatment of eye diseases
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017064121A1 (en) * 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
KR101880670B1 (ko) * 2015-11-06 2018-08-16 주식회사 모다이노칩 압력 센서를 구비하는 전자기기
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US20190231986A1 (en) * 2016-09-19 2019-08-01 Lupin Limited In-Line Filter For Protein/Peptide Drug Administration
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
CN111683682A (zh) 2018-02-02 2020-09-18 国立大学法人京都大学 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190317A (en) * 1877-05-01 Improvement in barbers chairs
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
WO2003068801A2 (en) * 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates

Similar Documents

Publication Publication Date Title
JP2010509369A5 (2)
JP2022031772A5 (2)
JP2015528454A5 (2)
JP2014506321A5 (2)
NZ596663A (en) Use of vegf antagonists in intraocular neovascular disease treatment
WO2007049017A3 (en) Agents that bind a target in pulmonary tissue for treating respiratory diseases
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
JP2016520573A5 (2)
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
JP2017528483A5 (2)
JP2014517050A5 (2)
Rotenberg et al. Redefining the timing of surgery for obstructive sleep apnea in anatomically favorable patients
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
WO2017031319A1 (en) Noradrenergic drug treatment of obstructive sleep apnea
JP2014503593A5 (2)
JP2012502103A5 (2)
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
JP2012522788A5 (2)
JP2018530574A5 (2)
JP2024503727A5 (2)
JP2022041802A5 (2)
JP2015522077A5 (2)
Custodio et al. Lack of clinically relevant effect of bictegravir (BIC, B) on metformin (MET) pharmacokinetics (PK) and pharmacodynamics (PD)
JP2017520562A5 (2)
Sockalingam et al. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study.